Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients

Liver

Volumn 20, Issue 1, 2000, Pages 51-59

  Møller, Søren ^a,b   Hansen, Erik F ^b   Becker, Ulrik ^b   Brinch, Kim ^a   Henriksen, Jens H ^a   Bendtsen, Flemming ^b  

^a Departments of Clinical Physiology   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cirrhosis; Haemodynamics; Hyperdynamic circulation; Oesophageal varices; Portal hypertension; Terlipressin; Vasoconstrictors; Vasodilatation; Vasopressin analogues

Indexed keywords

TERLIPRESSIN; VASOPRESSIN DERIVATIVE;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTERIAL PRESSURE; ARTERY COMPLIANCE; ARTICLE; BLOOD VOLUME; CIRCULATION TIME; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEART OUTPUT; HEART RATE; HEMODYNAMIC PARAMETERS; HUMAN; LIVER BLOOD FLOW; MALE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; SPLANCHNIC BLOOD FLOW; SYSTEMIC CIRCULATION; SYSTEMIC VASCULAR RESISTANCE;

ADULT; AGED; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS, ALCOHOLIC; LYSINE VASOPRESSIN; MALE; MIDDLE AGED; VASOCONSTRICTOR AGENTS;

EID: 0033982045     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0676.2000.020001051.x     Document Type: Article

References (37)

1. BOSCH J, PIZCUETA M P, FERNANDEZ M, et al. Hepatic, splanchnic and systemic haemodynamic abnormalities in portal hypertension. In: Shields R ed. Baillière's clinical gastroenterology. Portal hypertension. London: Baillière Tindall, 1992; 425-36.
2. MØLLER S. Systemic haemodynamics in cirrhosis and portal hypertension with focus on vasoactive substances and prognosis. Dan Med Bull 1998; 45: 1-14.
3. SCHRIER R W, ARROYO V, BERNARDI M, et al. Peripheral artery vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 5: 1151-7.
4. GROSZMANN R J. Vasodilatation and hyperdynamic circulatory state in chronic liver disease. In: Bosch J, Groszmann R J, eds. Portal hypertension. Pathophysiology and treatment. Oxford: Blackwell, 1994; 17-26.
5. HENRIKSEN J H, BENDTSEN F, SØRENSEN T I A, et al. Reduced central blood volume in cirrhosis. Gastroenterology 1989; 97: 1506-13.
6. HENRIKSEN J H, MØLLER S. Hemodynamics, distribution of blood volume, and kinetics of vasoactive substances in cirrhosis. In: Epstein M, ed. The kidney in liver disease. 4th Ed. Philadelphia: Hanley and Belfus, 1996; 241-58.
7. SALERNO F, DELBO A, MAGGI A, et al. Vasopressin release and water metabolism in patients with cirrhos:s. J Hepatol 1994; 21: 822-30.
8. SÖDERLUND C, MAGNUSSON I, TORNGREN S, et al. Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebocontrolled trial. Scand J Gastroenterol 1990; 25: 622-30.
9. FEU F, DELARBOL L R, BANARES R, et al. Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Gastroenterology 1996; 111: 1291-9.
10. GARCIA-COMPEAN D, BLANC P, BORIES J M, et al. Treatment of active gastroesophageal variceal bleeding with terlipressin or hemostatic balloon in patients with cirrhosis. A randomized controlled trial. Arch Med Res 1997; 28: 241-5.
11. FREEMAN J G, BARTON J R, RECORD C O. Haemodynamic responses to 1.25 and 2 mg of terlipressin intravenously in man. Aliment Pharmacol Ther 1988; 2: 361-7.
12. MOREAU R, CAILMAIL S, VALLA D, et al. Haemodynamic responses to a combination of terlipressin and octreotide in portal hypertensive rats. Aliment Pharmacol Ther 1997; 11: 993-7.
13. ESCORSELL A, BANDI J C, MOITINHO E, et al. Time profile of the haemodynamic effects of terlipressin in portal hypertension. J Hepatol 1997; 26: 621-7.
14. PAGLIARO L, BOSCH J, POLITI F, et al. Prevention and treatment of variceal bleeding: overview. In: Holstege A, Schölmerich J, Hahn E G, eds. Portal hypertension. Dordrecht: Kluwer, 1995; 235-66.
15. VACHIERY F, MOREAU R, GADANO A, et al. Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselective beta-blocker. Dig Dis Sci 1996; 41: 1722-6.
16. POUPON R, ISLAM S, CHRETIEN Y, et al. Effects of vasopressin on hepatic metabolic activity in cirrhosis. In: Lebrec D, Blei A T, eds. Vasopressin analogs and portal hypertension. Paris: John Libbey Eurotext, 1987; 75-82.
17. HENRIKSEN J H, RING-LARSEN H, KANSTRUP I-L, et al. Splanchnic and renal elimination and release of catecholamines in cirrhosis. Evidence of enhanced sympathetic nervous activity in patients with cirrhosis. Gut 1984; 25: 1034-43.
18. HENRIKSEN J H, WINKLER W. Hepatic blood flow determination. A comparison of 99-Tc-diethyl-IDA and indocyanine green as hepatic blood flow indicators in man. J Hepatol 1987; 4: 66-70.
19. MØLLER S, BENDTSEN F, HENRIKSEN J H. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995; 109: 1917-25.
20. DE SIMONE G, ROMAN M J, DANIELS S R, et al. Age-related changes in total arterial capacitance from birth to maturity in a normotensive population. Hypertension 1997; 29: 1213-7.
21. LASSEN N A, PERL W. Tracer kinetic methods in medical physiology. New York: Raven, 1979.
22. HUET M, VALLA D, LAFORTUNE M, et al. Hemodynamic effects of vasopressin in cirrhotic patients. In: Lebrec D, Blei A T, eds. Vasopressin analogs and portai hypertension. Paris: John Libbey Eurotext, 1987; 83-94.
23. BOSCH J, LEBREC D, JENKINS S A. Development of analogues: successes and failures. Scand J Gastroenterol 1998: 226: 3-13.
24. D'AMICO G, PAGLIARO L, BOSCH J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332-54.
25. GROSZMANN R J, KRAVETZ D, BOSCH J, et al. Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Hepatology 1982; 2: 757-62.
26. VOSMIK J, JEDLICKA K, MULDER J L, et al. Action of the triglycyl hormonogen of vasopressin (glypressin) in patients with liver cirrhosis and bleeding esophageal varices. Gastroenterology 1977; 72: 605-9.
27. VALLA D, LEE S S, MOREAU R, et al. Effects of glypressin on the splanchnic and systemic circulation in patients with cirrhosis. Gastroenterol Clin Biol 1985; 9: 877-80.
28. HANSEN E F, BECKER U, STRANDBERG C, et al. Effects of intravenous glypresssin on hepatic haemodynamics in anaesthetized pigs. J Hepatol 1997; 26: 98.
29. MOREAU R, SOUBRANE O, HADENGUE A, et al. Hemodynamic responses to the administration of terlipressin alone and combined with nitroglycerin in patients with cirrhosis. Gastroenterol Clin Biol 1992; 16: 680-6.
30. LEVACHER S, LETOUMELIN P, PATERON D, et al. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995; 346: 865-8.
31. GADANO A, MOREAU R, VACHIERY F, et al. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J Hepatol 1997; 26: 1229-34.
32. PASQUALETTI P, FESTUCCIA V, COLLACCIANI A, et al. Circadian rhythm of arginine vasopressin in hepatorenal syndrome. Nephron 1998; 78: 33-7.
33. AKRIVIADIS E A, ERVIN M G, COMINELLI F, et al. Hyponatremia of cirrhosis: role of vasopressin and decreased 'effective' plasma volume. Scand J Gastroenterol 1997; 32: 829-34.
34. MØLLER S, BENDTSEN F, CHRISTENSEN E, et al. Prognostic variables in patients with cirrhosis and oesophageal varices without prior bleeding. J Hepatol 1994; 21: 940 6.
35. BRAILLON A, CALES P, VALLA D, et al. Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis. Gut 1986; 27: 1204-9.
36. MOREAU R, HADENGUE A, SOUPISON T, et al. Abnormal pressor response to vasopressin in patients with cirrhosis: evidence for impaired buffering mechanisms. Hepatology 1990; 12: 7-12.
37. HEINEMANN A, STAUBER R E. Effect of terlipressin on in vitro vascular hyporeactivity of portal hypertensive rats. J Hepatol 1996; 24: 739-46.